GlaxoSmithKline makes substantial investments in its community and corporate citizenship programmes with the aim of enabling people to enjoy a better, healthier, more fulfilling lifestyle.

The company aspires to sustainability and systematically manages environment, health and safety concerns by integrating them into all aspects of its business. The company wants to build on the rich ethical heritage established by its former businesses in the way it conducts its operations and how it contributes to the communities of which it is a part. This heritage is retained in the new company’s identity which builds on the foundations of the previous companies whilst creating an identity and reputation worthy of a global leader.

Through its Global Community Partnerships, it will play a full and active part to meet some of society’s greatest challenges. These partnerships include efforts to tackle diseases such as malaria, lymphatic filariasis and HIV/AIDS.

HIV and AIDS GlaxoSmithKline is working with the United Nations agencies and other pharmaceutical companies to accelerate access to HIV and AIDS treatment and care in developing countries such as Senegal, Uganda and Rwanda. It is also working on preferential pricing programmes for use in international partnership initiatives with not-for-profit organisations and employers in Africa who can offer HIV/AIDS care and treatment directly to their staff through their own workplace clinics.

Vaccines The company is the leading provider of vaccines to the developing world and for nearly 20 years has been offering substantial discounts to governments, charities and agencies for public health programmes.

Lymphatic filariasis GlaxoSmithKline is providing funding, people and product as part of a global partnership to help eliminate the mosquito-borne disease, lymphatic filariasis (also known as LF or elephantiasis). In 2001, the company will ship around 50 million donated tablets of albendazole to 40 countries. Over the next 20 years, it is estimated this will become the single largest drug donation in the history of the pharmaceutical industry.

Children in nine countries will benefit from the company’s donation to a Project HOPE education programme aimed at providing mothers in developing countries with the basic information they need to recognise the danger signs of killer diseases.

Malaria The company is working with Roll Back Malaria and other partners to develop and implement innovative, sustainable plans to reduce malaria-related suffering and death. The company has been undertaking a pilot treatment programme in Kenya and Uganda using Malarone, as a second or third line anti-malarial.

Community programmes GlaxoSmithKline’s global programme of community investment helps communities improve their own social environments by working in partnership with not-for-profit organisations whose skills and resources complement the contributions of the company. The focus of the community programmes is on health education, children and improving access to healthcare.

Corporate donations As one of the largest companies in the UK, GlaxoSmithKline has a special commitment to the UK and will continue to support scientific education and medical research, healthcare charities, the environment and the arts. In 2001, the company will give £4.1 million to UK-based projects under its donation programme.